Theralink Technologies

Theralink Technologies is a precision medicine company specializing in phosphoproteomic technologies for cancer treatment. The company develops advanced biomarker assay services that measure the activation state of key drug targets and signaling pathways, enabling personalized treatment recommendations for cancer patients. Theralink's core mission is to transform cancer therapy by providing detailed molecular data to physicians, primarily serving the United States market.

Theralink Technologies has achieved significant advancements in the field of precision medicine through its innovative Reverse Phase Protein Array (RPPA) technology. This technology allows for precise mapping of protein drug target activation, which is crucial for tailoring cancer treatments to individual patients. The company's impact is evident in its contribution to more effective and personalized cancer therapies, positioning it as a leader in the molecular diagnostics and precision medicine sectors.